SLC5A2 and Hypoglycemia: On the other hand, aside from dipeptidyl peptidase-4 inhibitors, STOPP-J includes sulfonylureas, biguanides, thiazolidine derivatives, α-glucosidase inhibitors, and SGLT2 (sodium-glucose co-transporter-2) inhibitors due to the potential adverse effects of severe hypoglycemia, lactic acidosis, ileus, diarrhea, constipation, flatulence, dehydration, and urogenital infection [17].